Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV

被引:14
|
作者
Milic, Jovana [1 ,2 ]
Menozzi, Valentina [3 ]
Schepis, Filippo [4 ]
Malagoli, Andrea [1 ]
Besutti, Giulia [2 ]
Franconi, Iacopo [1 ]
Raimondi, Alessandro [1 ]
Carli, Federica [1 ]
Mussini, Cristina [1 ]
Sebastiani, Giada [5 ]
Guaraldi, Giovanni [1 ]
机构
[1] Univ Modena & Reggio Emilia, Modena HIV Metab Clin, Modena, Italy
[2] Univ Modena & Reggio Emilia, Clin & Expt Med PhD Program, Modena, Italy
[3] Univ Modena & Reggio Emilia, Modena, Italy
[4] Univ Modena & Reggio Emilia, Dept Gastroenterol, Modena, Italy
[5] McGill Univ, Dept Med, Div Gastroenterol & Hepatol, Hlth Ctr, Montreal, PQ, Canada
关键词
frailty; HIV; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; METABOLIC SYNDROME; STEATOHEPATITIS; MANAGEMENT; DIAGNOSIS; OBESITY; NAFLD;
D O I
10.1097/QAD.0000000000002650
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: The aim was to investigate the contribution of liver steatosis and significant fibrosis alone and in association [nonalcoholic fatty liver disease (NAFLD) with fibrosis] to frailty as a measure of biological age in people living with HIV (PLWH). Design: This was a cross-sectional study of consecutive patients attending Modena HIV Metabolic Clinic in 2018-2019. Methods: Patients with hazardous alcohol intake and viral hepatitis coinfection were excluded. Liver steatosis was diagnosed by controlled attenuation parameter (CAP), while liver fibrosis was diagnosed by liver stiffness measurement (LSM). NAFLD was defined as presence of liver steatosis (CAP >= 248 dB/m), while significant liver fibrosis or cirrhosis (stage >= F2) as LSM at least 7.1 kPa. Frailty was assessed using a 36-Item frailty index. Logistic regression was used to explore predictors of frailty using steatosis and fibrosis as covariates. Results: We analysed 707 PLWH (mean age 53.5 years, 76.2% men, median CD4(+) cell count 700 cells/mu l, 98.7% with undetectable HIV RNA). NAFLD with fibrosis was present in 10.2%; 18.9 and 3.9% of patients were classified as frail and most-frail, respectively. Univariate analysis demonstrated that neurocognitive impairment [odds ratio (OR) = 5.1, 1.6-15], vitamin D insufficiency (OR = 1.94, 1.2-3.2), obesity (OR = 8.1, 4.4-14.6), diabetes (OR = 3.2, 1.9-5.6), metabolic syndrome (OR = 2.41, 1.47-3.95) and osteoporosis (OR = 0.37, 0.16-0.76) were significantly associated with NAFLD with fibrosis. Predictors of frailty index included steatosis (OR = 2.1, 1.3-3.5), fibrosis (OR = 2, 1-3.7), NAFLD with fibrosis (OR = 9.2, 5.2-16.8), diabetes (OR = 1.7, 1-2.7) and multimorbidity (OR = 2.5, 1.5-4). Conclusion: Liver steatosis and NAFLD with fibrosis were associated with frailty. NAFLD with fibrosis exceeded multimorbidity in the prediction of frailty, suggesting the former as an indicator of metabolic age in PLWH. Copyright (C) 2020 Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码:1915 / 1921
页数:7
相关论文
共 50 条
  • [1] Nonalcoholic fatty liver disease and steatohepatitis in people living with HIV
    Squillace, Nicola
    Soria, Alessandro
    Bozzi, Giorgio
    Gori, Andrea
    Bandera, Alessandra
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 13 (07) : 643 - 650
  • [2] Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis With Liver Fibrosis as Predictors of New-Onset Diabetes Mellitus in People With HIV: A Longitudinal Cohort Study
    Han, Win Min
    Apornpong, Tanakorn
    Lwin, Hay Mar Su
    Thammapiwan, Siwat
    Boonrungsirisap, Jedsadakorn
    Gatechompol, Sivaporn
    Ubolyam, Sasiwimol
    Tangkijvanich, Pisit
    Kerr, Stephen J.
    Avihingsanon, Anchalee
    CLINICAL INFECTIOUS DISEASES, 2023, 77 (12) : 1687 - 1695
  • [3] Prevalence and Predictors of Nonalcoholic Fatty Liver Disease in Family Members of Patients With Nonalcoholic Fatty Liver Disease
    Anand, Abhinav
    Singh, Amit A.
    Elhence, Anshuman
    Vaishnav, Manas
    Biswas, Sagnik
    Gunjan, Deepak
    Gamanagatti, Shivanand R.
    Nayak, Baibaswata
    Kumar, Ramesh
    Shalimar
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2022, 12 (02) : 362 - 371
  • [4] Managing nonalcoholic fatty liver disease in patients living with HIV
    Tafesh, Zaid H.
    Verna, Elizabeth C.
    CURRENT OPINION IN INFECTIOUS DISEASES, 2017, 30 (01) : 12 - 20
  • [5] Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV
    Macias, Juan
    Frias, Mario
    Pineda, Juan Antonio
    Corona-Mata, Diana
    Corma-Gomez, Anais
    Rivero-Juarez, Antonio
    Santos, Marta
    Garcia-Deltoro, Miguel
    Rivero, Antonio
    Ricart-Olmos, Carmen
    Gonzalez-Serna, Alejandro
    Real, Luis Miguel
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2025, 61 (03) : 550 - 557
  • [6] Independent Predictors of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
    Hossain, Noreen
    Afendy, Arian
    Stepanova, Maria
    Nader, Fatema
    Srishord, Manirath
    Rafiq, Nila
    Goodman, Zachary
    Younossi, Zobair
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2009, 7 (11) : 1224 - 1229
  • [7] Nonalcoholic Fatty Liver Disease
    Isaacs, Scott
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2023, 52 (01) : 149 - 164
  • [8] Liver steatosis, but not fibrosis, is associated with insulin resistance in nonalcoholic fatty liver disease
    Sakurai M.
    Takamura T.
    Ota T.
    Ando H.
    Akahori H.
    Kaji K.
    Sasaki M.
    Nakanuma Y.
    Miura K.
    Kaneko S.
    Journal of Gastroenterology, 2007, 42 (4) : 312 - 317
  • [9] Liver steatosis, but not fibrosis, is associated with insulin resistance in nonalcoholic fatty liver disease
    Sakurai, Masaru
    Takamura, Toshinari
    Ota, Tsuguhito
    Ando, Hitoshi
    Akahori, Hiroshi
    Kaji, Kyosuke
    Sasaki, Motoko
    Nakanuma, Yasuni
    Miura, Katsuyuki
    Kaneko, Shuichi
    JOURNAL OF GASTROENTEROLOGY, 2007, 42 (04) : 312 - 317
  • [10] Metabolic dysfunction-associated fatty liver disease indicates more hepatic fibrosis than nonalcoholic fatty liver disease
    Hong, Shan
    Hong, Zifan
    Hao, Yiwei
    Sun, Lei
    Wei, Hongshan
    MEDICINE, 2025, 104 (06) : e41455